Investor List:

Top Diagnostics Series B Investors in New York City (14)

Know someone who's actively diligencing and investing? Add them to this list.
About this list
We’ve compiled a list of the top Diagnostics investors. The goal is to help Founders find the best investors to target and get introduced to.
Photo of Geoffrey Smith, Managing Partner at Digitalis Ventures
Geoffrey Smith
Digitalis Ventures·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY), Investors in Los Angeles (CA), Investors in San Francisco (CA), Investors in Boston (MA)
Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Diagnostics (Series A), Investors in Therapeutics (Seed), Investors in Diagnostics (Seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Therapeutics (Seed), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Series B), Investors in Diagnostics (Series B), Investors in Therapeutics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Diagnostics (Seed), Investors in Manufacturing (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Manufacturing (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in Manufacturing (Series B), Investors in Manufacturing (Series A), Investors in Manufacturing (Series A), Investors in Digital Health (Series B), Investors in BioTech (Series A), Investors in Manufacturing (Seed), Investors in BioTech (Series B), Investors in Digital Health (Series A), Investors in Manufacturing (Seed), Investors in Digital Health (Series A), Investors in Health IT (Series B), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Series B), Investors in Manufacturing (Seed), Investors in Manufacturing (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series B), Investors in Manufacturing (Series B), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Digital Health (Series B), Investors in Health & Hospital Services (Series A), Investors in BioTech (Seed), Investors in Health & Hospital Services (Series A), Investors in Digital Health (Seed), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Seed), Investors in Manufacturing (Series A), Investors in Manufacturing (Series B), Investors in BioTech (Series A), Investors in Health IT (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Seed), Investors in Digital Health (Series A), Investors in Manufacturing (Seed), Investors in Manufacturing (Series A), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Digital Health (Series B), Investors in Manufacturing (Seed), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in Digital Health (Series A), Investors in Health IT (Seed), Investors in Digital Health (Seed), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Series A), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Health IT (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in Health IT (Series A), Investors in Health IT (Seed), Investors in Los Angeles / Southern California (Other Lists), Investors in Boston / New England (Other Lists), Investors in New York City (Other Lists), Investors in San Francisco Bay Area (Other Lists)
Photo of George C. Petrocheilos, Managing Partner at Catalio Capital
George C. Petrocheilos
Catalio Capital·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Baltimore (MD), Investors in Athens (Greece), Investors in New York (NY)
Investors in Drug Delivery (Seed), Investors in Drug Delivery (Series B), Investors in Drug Delivery (Seed), Investors in Robotics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Drug Delivery (Series A), Investors in Diagnostics (Seed), Investors in Drug Delivery (Series B), Investors in Cybersecurity (Series B), Investors in Drug Delivery (Series A), Investors in Drug Delivery (Series B), Investors in Cybersecurity (Seed), Investors in Cybersecurity (Series A), Investors in Diagnostics (Series B), Investors in Drug Delivery (Series A), Investors in Medical Devices (Series A), Investors in Medical Devices (Series B), Investors in BioTech (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Medical Devices (Seed), Investors in Robotics (Series A), Investors in Drug Delivery (Seed), Investors in Robotics (Seed), Investors in Medical Devices (Series B), Investors in Diagnostics (Series B), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Medical Devices (Series A), Investors in Diagnostics (Series A), Investors in Cybersecurity (Seed), Investors in Medical Devices (Seed), Investors in Diagnostics (Seed), Investors in Cybersecurity (Series A), Investors in Cybersecurity (Series B), Investors in Robotics (Series B), Investors in BioTech (Series B), Investors in Robotics (Series A), Investors in Medical Devices (Series B), Investors in Robotics (Seed), Investors in BioTech (Series A), Investors in Robotics (Series B), Investors in Cybersecurity (Series B), Investors in Medical Devices (Series A), Investors in BioTech (Seed), Investors in Medical Devices (Seed), Investors in Cybersecurity (Series A), Investors in Cybersecurity (Seed), Investors in Robotics (Series A), Investors in Washington, D.C. (Other Lists), Investors in BioTech (Series B), Investors in Robotics (Seed), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in New York City (Other Lists)
Photo of Cris De Luca, Partner at Sanofi Ventures
Cris De Luca
Sweet spot: $7.5M
Range: $5.0M - $10.0M
Investors in Paris (France), Investors in Israel, Investors in New York (NY), Investors in Europe, Investors in San Francisco (CA), Investors in Cambridge (MA)
Investors in Diagnostics (Series B), Investors in Pharmaceuticals (Series B), Investors in Diagnostics (Series A), Investors in Pharmaceuticals (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Medical Devices (Series B), Investors in Medical Devices (Series B), Investors in Medical Devices (Series A), Investors in Diagnostics (Series A), Investors in AR/VR (Series B), Investors in AR/VR (Series B), Investors in Consumer Health (Series B), Investors in Diagnostics (Series B), Investors in Medical Devices (Series B), Investors in Digital Health (Series B), Investors in Health IT (Series B), Investors in IoT (Series B), Investors in AR/VR (Series A), Investors in AR/VR (Series A), Investors in Medical Devices (Series A), Investors in Diagnostics (Series B), Investors in Pharmaceuticals (Series B), Investors in Diagnostics (Series A), Investors in Pharmaceuticals (Series B), Investors in Medical Devices (Series B), Investors in Diagnostics (Series A), Investors in Consumer Health (Series B), Investors in AR/VR (Series B), Investors in Digital Health (Series A), Investors in Medical Devices (Series A), Investors in IoT (Series B), Investors in Pharmaceuticals (Series A), Investors in IoT (Series A), Investors in Health IT (Series A), Investors in Pharmaceuticals (Series B), Investors in Consumer Health (Series A), Investors in AR/VR (Series A), Investors in AR/VR (Series B), Investors in Pharmaceuticals (Series A), Investors in IoT (Series B), Investors in Digital Health (Series B), Investors in IoT (Series A), Investors in AI (Series B), Investors in Consumer Health (Series A), Investors in Consumer Health (Series B), Investors in Medical Devices (Series A), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in IoT (Series A), Investors in Medical Devices (Series B), Investors in Pharmaceuticals (Series A), Investors in Digital Health (Series B), Investors in IoT (Series B), Investors in AI (Series B), Investors in Pharmaceuticals (Series B), Investors in AR/VR (Series A), Investors in Health IT (Series A), Investors in AR/VR (Series B), Investors in AI (Series A), Investors in Consumer Health (Series B), Investors in Health IT (Series B), Investors in Digital Health (Series B), Investors in Digital Health (Series A), Investors in Consumer Health (Series A), Investors in AI (Series A), Investors in Medical Devices (Series A), Investors in AI (Series B), Investors in IoT (Series A), Investors in Consumer Health (Series B), Investors in Pharmaceuticals (Series A), Investors in IoT (Series B), Investors in AR/VR (Series A), Investors in Digital Health (Series A), Investors in Health IT (Series B), Investors in Consumer Health (Series A), Investors in Health IT (Series A), Investors in AI (Series A), Investors in Digital Health (Series B), Investors in Israel (Other Lists), Investors in AI (Series B), Investors in IoT (Series A), Investors in Consumer Health (Series A), Investors in Health IT (Series A), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Diverse Investors (Other Lists), Investors in Boston / New England (Other Lists), Investors in Investors who were founders (Other Lists), Investors in AI (Series A), Investors in AI (Series B), Investors in Investors who invested in female founders (Other Lists), Investors in Investors who invested in diverse founders (Other Lists), Investors in Health IT (Series A), Investors in New York City (Other Lists), Investors in AI (Series A), Investors in San Francisco Bay Area (Other Lists)
Photo of Anurag Kondapalli, Principal at RA Capital
Anurag Kondapalli
RA Capital·Principal
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY)
Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in New York City (Other Lists)
Photo of Matt Cohen, Partner at Osage University Partners
Matt Cohen
Sweet spot: $7.5M
Range: $5.0M - $10.0M
Investors in Philadelphia (PA)
Investors in Diagnostics (Pre-seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Seed), Investors in Diagnostics (Series A), Investors in Medical Devices (Pre-seed), Investors in Medical Devices (Series B), Investors in Diagnostics (Pre-seed), Investors in Diagnostics (Series B), Investors in Digital Health (Pre-seed), Investors in Medical Devices (Seed), Investors in Medical Devices (Series A), Investors in Health & Hospital Services (Pre-seed), Investors in Diagnostics (Series A), Investors in Digital Health (Series B), Investors in Diagnostics (Seed), Investors in Health IT (Pre-seed), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Medical Devices (Series B), Investors in Medical Devices (Pre-seed), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Pre-seed), Investors in Health IT (Series A), Investors in Medical Devices (Series A), Investors in Health IT (Seed), Investors in Health & Hospital Services (Pre-seed), Investors in Medical Devices (Seed), Investors in Health IT (Pre-seed), Investors in Digital Health (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Digital Health (Seed), Investors in Digital Health (Series A), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in Health IT (Series A), Investors in Health IT (Seed), Investors in New York City (Other Lists)
Photo of Nishant Rastogi, Vice President at New Rhein Healthcare Investors
Nishant Rastogi
Sweet spot: $1.5M
Range: $1M - $5.0M
Investors in Philadelphia (PA)
Investors in Diagnostics (Series B), Investors in Impact (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Pharmaceuticals (Series B), Investors in Medical Devices (Series B), Investors in Impact (Series A), Investors in Impact (Seed), Investors in Medical Devices (Series A), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series A), Investors in Diagnostics (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in Impact (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in BioTech (Series A), Investors in Medical Devices (Series B), Investors in BioTech (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Pharmaceuticals (Series B), Investors in Impact (Series A), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Pharmaceuticals (Series A), Investors in Health IT (Series A), Investors in Medical Devices (Series A), Investors in Digital Health (Series B), Investors in Impact (Seed), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in Health IT (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in Health IT (Seed), Investors in Health & Hospital Services (Seed), Investors in New York City (Other Lists)
Photo of Jesse Treu, Partner at Domain Associates
Jesse Treu
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York City
Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series A), Investors in Diagnostics (Series B), Investors in BioTech (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in BioTech (Series A), Investors in New York City (Other Lists), Investors in BioTech (Seed)
Photo of Emily Minkow, Venture Partner at RA Capital
Emily Minkow
RA Capital·Venture Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY)
Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Pharmaceuticals (Series B), Investors in Medical Devices (Series B), Investors in Medical Devices (Series A), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series A), Investors in Diagnostics (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Seed), Investors in Medical Devices (Series B), Investors in Health & Hospital Services (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series A), Investors in Health IT (Series A), Investors in Health IT (Seed), Investors in Pharmaceuticals (Seed), Investors in Medical Devices (Series A), Investors in Medical Devices (Seed), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Digital Health (Series B), Investors in Health & Hospital Services (Series B), Investors in New York City (Other Lists), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed)